TELK -- Telik, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TELK -- Telik, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (352)	8/29/2003 12:01:04 PM
From: tuck	Read Replies (1) of 887

>>So far I am not impressed with TLK-16998. Have no idea how is L7 doing.<< Telik is apparently not that impressed, either, as they have chosen to advance a different (but similar MOA) molecule: Message 17818830 At least I think it's different (I haven't noticed any phrases like "formerly TLK-16998"). I haven't found anything about it since the article Wilder cited a while back: Message 18226207 Any thoughts on this molecule? FWIW, I can't find anything new on Merck's L7, either, which is no surprise. But it's an agonist of the IR-B, and thus has potential for hypoglycemia. Telik compounds seem superior to it. If you're still not impressed, what program do you like better? Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next